Healthcare
Nuvalent, Inc.(NUVL)
Live Price
Offline$123.43
+0.06% today
1Y Change
+56.00%
Window
Jun 26, 2025 โ Jun 23, 2026
- Market Cap
- $7.25B
- Revenue Growth
- 0.0%
- EPS Growth
- -48.9%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 26, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nuvalent, Inc. (NUVL) is a Healthcare stock with a market cap of $7.25B and listed on NASDAQ. The stock last traded around $123.43 and up 56.0% across the available one-year price window (Jun 26, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -48.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -48.9%, free cash flow -48.7% with operating margin 0.0% and ROIC -31.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines NUVL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -48.9%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +2.8% | +2.0% | -11.2% |
2026 Feb 26, 2026 | +12.8% | -1.9% | -3.7% | -5.6% |
2025 Oct 30, 2025 | -22.3% | +1.2% | -2.3% | +11.4% |
Benchmark Edge
NUVL vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NUVL
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NUVL Max Drawdown
-20.98%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NUVL and SPY.
Company Overview
Nuvalent, Inc.
NASDAQ Global Select
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
- Leadership
- James R. Porter
- IPO Date
- Jul 29, 2021
- Employees
- 162
- Street Address
- One Broadway
- Mailing
- Cambridge, MA, 02142
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 857 357 7000
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 6.0
Growth
- Revenue
- 0.0%
- EPS
- -48.9%
- Free Cash Flow
- -48.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -42.1%
- ROIC
- -31.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 15.27
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.